Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients.
Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients.
复制标题
肿瘤 SOCS3 甲基化状态预测 HCC 患者对 TACE 的治疗反应和预后
DOI：
10.18632/oncotarget.16157
复制
发表时间：
2017-04-25
期刊：
影响因子：
--
通讯作者：
Zhou WP
中科院分区：
文献类型：
--
作者：
Jiang BG;Wang N;Huang J;Yang Y;Sun LL;Pan ZY;Zhou WP
背景细胞因子信号转导抑制因子（SOCS）1和3甲基化与癌症患者的临床特征和预后相关。然而，它们在确定肝细胞癌（HCC）患者经动脉化疗栓塞（TACE）治疗反应中的作用仍然未知。结果SOCS3基因甲基化与肝癌患者的临床分期、淋巴结转移和血管浸润密切相关。值得注意的是，我们观察到SOCS3甲基化的存在与TACE反应密切相关。在预后分析中，SOCS3甲基化存在的HCC患者的预后较差，其3年和5年生存率较低，平均生存期较短。多变量考克斯分析证实了SOCS 3甲基化在接受TACE治疗的HCC患者中的预后作用。资料与方法246例接受TACE治疗的HCC患者纳入本研究。从回波引导的细针抽吸获得肿瘤样品，并纯化来自肿瘤样品的基因组DNA。采用甲基化特异性聚合酶链反应检测SOCS1和SOCS3甲基化状态。术后评估患者对TACE的治疗反应，并随访分析患者的预后。结论SOCS3基因甲基化可作为肝癌患者TACE治疗效果及预后的预测指标。
Background Suppressor of cytokine signaling (SOCS) 1 and 3 methylation have been associated with clinical features and outcomes of cancer patients. However, their roles in determining the treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) remain unknown. Results We found that presence of SOCS3 methylation is significantly associated with the major clinical features of HCC patients, including tumor stage, lymph node and vascular invasion. Of note, we observed that the presence of SOCS3 methylation is closely related to TACE response. In prognosis analyses, HCC patients with SOCS3 methylation presence have a poorer prognosis indicated by lower 3-, and 5-year survival rates and shorter mean survival period, than those without. Multivariate COX analysis confirms the prognostic role of the presence of SOCS3 methylation in HCC patients receiving TACE treatment. Materials and Methods A total of 246 HCC patients receiving TACE were enrolled in this study. Tumor samples was obtained from echo-guided fine needle aspiration and genomic DNA from tumor samples was purified. SOCS1 and SOCS3 methylation status were detected using methylation-specific polymerase chain reaction. The treatment responses to TACE of patients were evaluated after procedure and all patients were followed for prognosis analysis. Conclusions This finding suggests that the presence of SOCS3 methylation is a marker to predict treatment response and prognosis in HCC patients receiving TACE therapy.